<DOC>
	<DOCNO>NCT01168674</DOCNO>
	<brief_summary>The primary outcome study determine predictor response select population patient MDD effectively treatable augmentation ziprasidone . Major depressive disorder ( MDD ) broad category , include many form depressive illness , include single major depressive episode , episodic recurrence intervene well state , chronic depressive/anxious state without intervene euthymia , manic symptom meet threshold definition full mania/hypomania . In heterogenous , large diagnostic definition , important group patient appear respond well antidepressant , , conversely , base observational study , may respond well neuroleptic . These predictor response begin identify may serve good design study neuroleptics depressive illness . Among predictor response MDD clinical feature similar bipolar illness unipolar depression . These include family history bipolar disorder , antidepressant-induced mania , highly recurrent depressive episode ( &gt; 5 ) , atypical depression , early age onset depression ( &lt; age 20 ) , failure respond antidepressant , antidepressant tolerance ( initial response follow later loss response ) . The investigator propose use predictor pick patient likely respond Geodon MDD . This first RCT predictor depressive response apply neuroleptic .</brief_summary>
	<brief_title>Predictors Response Augmentation With Ziprasidone ( Geodon® ) Major Depressive Disorder</brief_title>
	<detailed_description>This three-site , block randomize ( 1:1 ratio ) double-blind , placebo-controlled prospective cross-over study 50 subject . Patients randomize receive ziprasidone-washout-placebo placebo- washout-ziprasidone 13-weeks . Primary Secondary safety outcome : The primary outcome measure change baseline Montgomery-Asberg Depression Rating Scale ( MADRS ) score end treatment . Safety outcomes determine spontaneously report adverse event case report form .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>1 . Age 1870 year . 2 . If female , nonpregnant/nonlactating 3 . If sexually active female reproductive potential , must use adequate contraception ( i.e. , oral contraceptive , barrier protection , prior tubal ligation ) 4 . Currently meet DSMIV criterion major depressive episode , nonpsychotic . 5 . Having least 3 follow criterion list predictor depressive response neuroleptic : family history bipolar disorder , antidepressantinduced mania , highly recurrent depressive episode ( &gt; 5 ) , atypical depression , early age onset depression ( &lt; age 20 ) , failure respond antidepressant , antidepressant tolerance ( initial response follow later loss response ) . Inadequate response antidepressant identify follow : score ≥14 17item HAMD CGIS score ≥ 3 retrospective confirmation adequate trial single antidepressant ( define ≥ 6week trial acceptable therapeutic dose [ ≥ 40 mg fluoxetine , paroxetine citalopram , 20 mg escitalopram , 60 mg duloxetine , 37.5 mg paroxetine CR , 150 mg sertraline , 100 mg fluvoxamine , 225 mg venlafaxine XR , 30 mg mirtazapine , 300 mg bupropion , 75 mg nortriptyline , 20 mg protriptyline , 100 mg amitriptyline imipramine ) 1 . Bipolar depression 2 . Sensitivity failure respond ziprasidone history ziprasidone use previous 3 month 3 . Active substance abuse dependence previous 3 month 4 . Psychotic disorder 5 . Serious suicidality evidence score 3 great suicide item MADRS 6 . Medically unstable judged study investigator 7 . Lack capacity provide inform , write , consent investigator 8 . Previous diagnosed cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>Bipolar Disorder</keyword>
	<keyword>BD</keyword>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Disorder Bipolar feature</keyword>
</DOC>